Polymorphous low-grade adenocarcinoma
A type of salivary gland cancer
| Classification |
|
|---|---|
| External resources |
|
Polymorphous low-grade adenocarcinoma (PLGA) is a rare type of salivary gland cancer that is characterized by its slow growth and low potential for metastasis. It primarily affects the minor salivary glands, particularly in the oral cavity.
Presentation[edit | edit source]
PLGA typically presents as a painless, slow-growing mass in the oral cavity. It most commonly occurs in the palate, but can also be found in other areas such as the buccal mucosa, upper lip, and retromolar area. Patients may notice a firm, nodular swelling that is often asymptomatic until it reaches a significant size.
Histopathology[edit | edit source]
The histological appearance of PLGA is characterized by a diverse architectural pattern, which can include tubular, papillary, cribriform, and solid structures. The tumor cells are generally uniform with bland nuclear features, and the stroma is often fibrous. Despite its varied histological patterns, PLGA is distinguished by its low-grade cytological features and infiltrative growth pattern.
Diagnosis[edit | edit source]
Diagnosis of PLGA is primarily based on histopathological examination. A biopsy of the lesion is performed, and the tissue is examined under a microscope. Immunohistochemical staining can aid in differentiating PLGA from other salivary gland tumors, such as adenoid cystic carcinoma and mucoepidermoid carcinoma.
Treatment[edit | edit source]
The primary treatment for PLGA is surgical excision with clear margins. Due to its low-grade nature, PLGA has a good prognosis when completely excised. Recurrence is possible if the tumor is not fully removed, but metastasis is rare. In cases where surgical margins are positive or the tumor is in a location that makes complete excision difficult, radiation therapy may be considered.
Prognosis[edit | edit source]
The prognosis for patients with PLGA is generally favorable, with high survival rates. The risk of recurrence is low if the tumor is adequately excised. Long-term follow-up is recommended to monitor for any signs of recurrence.
Related pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
